Everyone’s suddenly “not hungry,” and we have questions. In this episode, we break down GLP-1 medications, the myths, the side effects nobody posts about, and why “start low and go slow” is not a suggestion — it’s a lifestyle.

References

Abu-Nejim, H. (2025). Current perspectives on GLP-1 receptor agonists in contemporary therapeutics. Journal of Clinical Medicine, 14(3), 455–468. https://pmc.ncbi.nlm.nih.gov/articles/PMC12511252/

Advisory Board. (2026, January 12). The biggest health trends in 2026. https://www.advisory.com/daily-briefing/2026/01/12/health-trends

Associated Press. (2026, January 14). Food companies target users of weight-loss drugs with “GLP-1 friendly” labels. https://apnews.com/article/5bb5dfaae3778b1968c1793326e8ba73

IQVIA. (2026, January). Outlook for obesity in 2026: From consolidation to innovation. https://www.iqvia.com/locations/emea/blogs/2026/01/outlook-for-obesity-in-2026

Moiz, A. (2025). The expanding role of GLP-1 receptor agonists. Frontiers in Endocrinology, 16, 112233. https://pmc.ncbi.nlm.nih.gov/articles/PMC12303005/

Reiss, A. B. (2025). Weight reduction with GLP-1 agonists and paths for future obesity therapies. International Journal of Obesity, 49(2), 215–224. https://pmc.ncbi.nlm.nih.gov/articles/PMC11940170/

Reuters. (2026, January 7). Study finds weight and health issues return after stopping obesity drugs. https://www.reuters.com/business/healthcare-pharmaceuticals/less-than-two-years-after-stopping-obesity-drugs-weight-health-issues-return-2026-01-07/

Reuters. (2026, January 14). AbbVie plans to build out its presence in obesity market. https://www.reuters.com/business/healthcare-pharmaceuticals/abbvie-plans-build-out-its-presence-obesity-market-2026-01-14/

Trujillo, J. M., & Nuffer, W. (2021). GLP-1 receptor agonists: An updated review of head-to-head clinical studies. Therapeutic Advances in Endocrinology and Metabolism, 12, 1–16. https://pmc.ncbi.nlm.nih.gov/articles/PMC7953228/

U.S. News & World Report. (2026, January 6). GLP-1 ranks as No. 1 health trend for 2026. https://www.foodbusinessnews.net/articles/29573-glp-1-ranks-as-no-1-health-trend-for-2026

World Health Organization. (2025, December 1). WHO issues global guideline on the use of GLP-1 medicines in treating obesity. https://www.who.int/news/item/01-12-2025-who-issues-global-guideline-on-the-use-of-glp-1-medicines-in-treating-obesity

#NurseChatDiaries
#GLP1
#StartLowGoSlow
#HealthPodcast
#HealthcareTalk
#WeightLossMyths
#MedicalHumor
#HealthEducation
#NurseLife
#WellnessWithoutJudgment#ozempic